[go: up one dir, main page]

HUE041944T2 - Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére - Google Patents

Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére

Info

Publication number
HUE041944T2
HUE041944T2 HUE09837849A HUE09837849A HUE041944T2 HU E041944 T2 HUE041944 T2 HU E041944T2 HU E09837849 A HUE09837849 A HU E09837849A HU E09837849 A HUE09837849 A HU E09837849A HU E041944 T2 HUE041944 T2 HU E041944T2
Authority
HU
Hungary
Prior art keywords
treatment
low dose
actinic keratosis
dosing method
imiquimod formulations
Prior art date
Application number
HUE09837849A
Other languages
English (en)
Inventor
Michael Nordsiek
Sharon Levy
James Lee
James Kulp
Kodumudi Balaji
Tze-Chiang Meng
Jason Wu
Valyn Bahm
Robert Babilon
Original Assignee
Medicis Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42316709&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE041944(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medicis Pharmaceutical Corp filed Critical Medicis Pharmaceutical Corp
Publication of HUE041944T2 publication Critical patent/HUE041944T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
HUE09837849A 2008-12-19 2009-12-11 Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére HUE041944T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13953608P 2008-12-19 2008-12-19
US14473109P 2009-01-14 2009-01-14
US20514509P 2009-01-15 2009-01-15

Publications (1)

Publication Number Publication Date
HUE041944T2 true HUE041944T2 (hu) 2019-06-28

Family

ID=42316709

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE09837849A HUE041944T2 (hu) 2008-12-19 2009-12-11 Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére

Country Status (28)

Country Link
US (13) US20110021555A1 (hu)
EP (1) EP2378876B1 (hu)
AR (1) AR074802A1 (hu)
AU (1) AU2009335943A1 (hu)
BR (1) BRPI0923164A2 (hu)
CL (1) CL2009002183A1 (hu)
CO (1) CO6400171A2 (hu)
CR (1) CR20110338A (hu)
CY (1) CY1121485T1 (hu)
DK (1) DK2378876T3 (hu)
DO (1) DOP2011000195A (hu)
EA (1) EA201100984A1 (hu)
ES (1) ES2720149T3 (hu)
GE (1) GEP20146198B (hu)
HR (1) HRP20190306T1 (hu)
HU (1) HUE041944T2 (hu)
IL (2) IL213628A (hu)
LT (1) LT2378876T (hu)
MX (2) MX346455B (hu)
PA (1) PA8855101A1 (hu)
PE (2) PE20100469A1 (hu)
PL (1) PL2378876T3 (hu)
PT (1) PT2378876T (hu)
RS (1) RS58566B1 (hu)
SI (1) SI2378876T1 (hu)
SM (1) SMT201900195T1 (hu)
TW (1) TWI442923B (hu)
WO (1) WO2010080345A1 (hu)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US20110030104A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Nucleic acids encoding plant glutamine phenylpyruvate transaminase (GPT) and uses thereof
US20110030089A1 (en) 2008-08-29 2011-02-03 Los Alamos National Security, Llc Transgenic plants with enhanced growth characteristics
MX346455B (es) 2008-12-19 2017-03-21 Medicis Pharmaceutical Corp Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
EP2453747B1 (en) * 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
DK2584900T3 (en) * 2010-06-25 2019-04-01 Medicis Pharmaceutical Corp Combination therapy with cryosurgery and low-dose imiquimod for the treatment of actinic keratosis
US9072876B2 (en) 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis
DK2785336T3 (da) * 2011-11-30 2016-01-11 Merz Pharma Gmbh & Co Kgaa Anvendelse af pegylerede alkoholer til behandling af aktinisk keratose
AU2013252785B2 (en) 2012-04-27 2017-05-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of CpG oligonucleotides co-formulated with an antibiotic to accelarate wound healing
KR102585409B1 (ko) 2013-08-30 2023-10-05 이뮤노젠 아이엔씨 엽산 수용체 1의 검출을 위한 항체 및 분석
US9711014B2 (en) 2013-09-06 2017-07-18 Immersion Corporation Systems and methods for generating haptic effects associated with transitions in audio signals
US9576445B2 (en) 2013-09-06 2017-02-21 Immersion Corp. Systems and methods for generating haptic effects associated with an envelope in audio signals
US9619980B2 (en) 2013-09-06 2017-04-11 Immersion Corporation Systems and methods for generating haptic effects associated with audio signals
SI3055332T1 (sl) * 2013-10-08 2020-02-28 Immunogen, Inc. Režim odmerjanja imunokonjugata ANTI-FOLR1
KR102573972B1 (ko) * 2014-09-10 2023-09-01 워싱턴 유니버시티 전암성 피부 병변의 치료를 위한 조성물과 방법
WO2017049149A1 (en) 2015-09-17 2017-03-23 Immunogen, Inc. Therapeutic combinations comprising anti-folr1 immunoconjugates
KR20240090837A (ko) * 2017-03-10 2024-06-21 에이티엔엑스 에스피브이, 엘엘씨 광선 각화증의 치료 및/또는 예방 방법
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE24906E (en) 1955-11-18 1960-12-13 Pressure-sensitive adhesive sheet material
US4722941A (en) 1978-06-07 1988-02-02 Kali-Chemie Pharma Gmbh Readily absorbable pharmaceutical compositions of per se poorly absorbable pharmacologically active agents and preparation thereof
US4411893A (en) * 1981-08-14 1983-10-25 Minnesota Mining And Manufacturing Company Topical medicament preparations
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4751087A (en) 1985-04-19 1988-06-14 Riker Laboratories, Inc. Transdermal nitroglycerin delivery system
US4746515A (en) 1987-02-26 1988-05-24 Alza Corporation Skin permeation enhancer compositions using glycerol monolaurate
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
SE9601528D0 (sv) 1996-04-23 1996-04-23 Pharmacia Ab Transdermally administered dextromethorphan as antitissue agent
UA67760C2 (uk) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US20030007939A1 (en) * 1998-07-31 2003-01-09 Howard Murad Pharmaceutical compositions and methods for managing dermatological conditions
US6245776B1 (en) 1999-01-08 2001-06-12 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) * 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6894060B2 (en) * 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) * 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
WO2002102377A1 (en) 2001-06-15 2002-12-27 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease
CN100473384C (zh) * 2001-11-29 2009-04-01 3M创新有限公司 包括免疫反应改性剂的药物制剂
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7893083B2 (en) * 2003-01-06 2011-02-22 Eugene Mandrea Method of treating genital herpes
KR20050109562A (ko) * 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
US7699057B2 (en) * 2003-03-13 2010-04-20 3M Innovative Properties Company Methods for treating skin lesions
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7521459B2 (en) 2003-07-28 2009-04-21 Metabeauty Inc. Method for treating damaged skin
US20090232755A1 (en) * 2003-07-28 2009-09-17 Leslie Baumann Combination therapies for treating photodamaged skin
AU2004268665A1 (en) 2003-09-02 2005-03-10 3M Innovative Properties Company Methods related to the treatment of mucosal associated conditions
AU2004312547A1 (en) 2003-12-31 2005-07-21 Taigen Biotechnology Protease inhibitors
US20070134273A1 (en) * 2004-02-10 2007-06-14 Francois Romagne Composition and method for the treatment of carcinoma
US20080125485A1 (en) * 2004-02-17 2008-05-29 Action Medicines Use of 2,5-Dihydroxybenzene Derivatives for Treating Actinic Keratosis
WO2005110013A2 (en) * 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
US20070196452A1 (en) 2004-06-07 2007-08-23 Jie Zhang Flux-enabling compositions and methods for dermal delivery of drugs
CN1286529C (zh) 2004-06-11 2006-11-29 华中科技大学 具有皮肤靶向性的药物组合物及其制备方法和用途
US20060062755A1 (en) * 2004-09-21 2006-03-23 Woodward John R Method of cancer screening; method of cancer treatment; and method of diabetes treatment
DE102004049223A1 (de) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
US20060105028A1 (en) * 2004-11-12 2006-05-18 Jie Zhang Systems and methods for treating warts
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
BRPI0615588A2 (pt) * 2005-08-31 2011-05-24 Serentis Ltd uso de um inibidor de aureolisina para o tratamento de condições inflamatórias da pele caracterizadas por colonização com staphylococcus aureus
US8889154B2 (en) 2005-09-15 2014-11-18 Medicis Pharmaceutical Corporation Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation
WO2007032009A2 (en) * 2005-09-15 2007-03-22 Biomas Ltd. Use of tellurium compounds for treatment of basal cell carcinoma and/or actinic keratosis
US20070081962A1 (en) 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
GB0524962D0 (en) * 2005-12-07 2006-01-18 Pharmakodex Ltd Topical pharmaceutical compositions
US20070264317A1 (en) 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
US9023863B2 (en) * 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
EP1889609B1 (en) 2006-07-18 2019-05-22 Meda AB Immune response modifier foam formulations
WO2008016475A2 (en) 2006-07-31 2008-02-07 3M Innovative Properties Company Immune response modifier compositions and methods
PL2076260T3 (pl) * 2006-09-15 2011-08-31 Celgene Corp Związki N-metyloaminometylo-izoindolu, kompozycje zawierające te związki, oraz metody ich stosowania
ZA200901950B (en) * 2006-09-26 2010-06-30 Celgene Corp 5-substituted quinazolinone derivatives as antitumor agents
PL2115140T3 (pl) * 2007-01-31 2017-03-31 Yu Dodatnio naładowane rozpuszczalne w wodzie proleki 1H-imidazo[4,5-c]chinolino-4-amin i powiązane związki o bardzo wysokich wskaźnikach penetracji przez skórę
WO2008098232A1 (en) * 2007-02-08 2008-08-14 Graceway Pharmaceuticals, Llc Methods of treating dermatological disorders and inducing interferon biosynthesis with shorter durations of imiquimod therapy
WO2008118765A1 (en) 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Methods and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
CA2679067A1 (en) * 2007-03-23 2008-10-02 Graceway Pharmaceuticals, Llc Method and packages to enhance safety when using imiquimod to treat children diagnosed with skin disorders
WO2008140713A1 (en) 2007-05-08 2008-11-20 The Brigham And Women's Hospital, Inc Methods and products for treating proliferative disorders
US8636982B2 (en) * 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
GB0715428D0 (en) 2007-08-08 2007-09-19 Imp Innovations Ltd Compositions and uses thereof
US20090130029A1 (en) * 2007-11-21 2009-05-21 Foamix Ltd. Glycerol ethers vehicle and pharmaceutical compositions thereof
US9439857B2 (en) * 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
CA2708203A1 (en) * 2008-01-15 2009-07-23 Dow Pharmaceutical Sciences, Inc. Imiquimod formulation
ES2537703T3 (es) 2008-01-31 2015-06-11 Curevac Gmbh Ácidos nucleicos que comprenden la fórmula (NuGlXmGnNv)a y sus derivados como agentes/adyuvantes inmunoestimuladores
US20090246156A1 (en) * 2008-03-31 2009-10-01 Audrey Kunin Anti-acne sunscreen composition
WO2009145841A1 (en) * 2008-04-03 2009-12-03 Cognate 3, Llc Compositions and methods for immunotherapy
WO2009134769A1 (en) 2008-04-28 2009-11-05 Novartis Ag Nanoparticles for use in pharmaceutical compositions
WO2009155070A2 (en) 2008-05-30 2009-12-23 Novelix Pharmaceuticals, Inc. Compositions and methods for treatment of inflammation and hyperkeratotic lesions
CN102076333A (zh) 2008-06-26 2011-05-25 安特里奥公司 真皮递送
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
WO2010050889A1 (en) 2008-10-31 2010-05-06 Moberg Derma Ab Topical composition comprising a combination of at least two penetration enhancing agents
MX346455B (es) * 2008-12-19 2017-03-21 Medicis Pharmaceutical Corp Formulaciones de imiquimod de baja concentracion de dosis y regimenes de dosis de corta duracion para tratar queratosis actinica.
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
EP2453747B1 (en) 2009-07-13 2017-08-30 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds
US9072876B2 (en) * 2010-08-05 2015-07-07 Medicis Pharmaceutical Corporation Pump systems and methods for storing and dispensing a plurality of precisely measured unit-doses of imiquimod cream
US9492682B2 (en) * 2011-09-14 2016-11-15 Medicis Pharmaceutical Corporation Combination therapy with low dosage strength imiquimod and photodynamic therapy to treat actinic keratosis

Also Published As

Publication number Publication date
EP2378876B1 (en) 2018-11-14
IL255163A0 (en) 2017-12-31
HRP20190306T1 (hr) 2019-05-03
WO2010080345A1 (en) 2010-07-15
US20110263636A1 (en) 2011-10-27
AR074802A1 (es) 2011-02-16
PE20100469A1 (es) 2010-07-31
TW201040173A (en) 2010-11-16
TWI442923B (zh) 2014-07-01
DK2378876T3 (en) 2019-03-11
SMT201900195T1 (it) 2019-05-10
GEP20146198B (en) 2014-11-25
CR20110338A (es) 2011-11-10
PE20142367A1 (es) 2015-01-10
US20110263637A1 (en) 2011-10-27
US11318130B2 (en) 2022-05-03
IL213628A0 (en) 2011-07-31
CY1121485T1 (el) 2020-05-29
US20130210855A1 (en) 2013-08-15
US9370509B2 (en) 2016-06-21
PL2378876T3 (pl) 2019-06-28
US20110263635A1 (en) 2011-10-27
CL2009002183A1 (es) 2011-01-07
US20110263634A1 (en) 2011-10-27
EA201100984A1 (ru) 2012-01-30
LT2378876T (lt) 2019-04-25
BRPI0923164A2 (pt) 2016-01-26
US20160303111A1 (en) 2016-10-20
US20110257219A1 (en) 2011-10-20
US20110263633A1 (en) 2011-10-27
PT2378876T (pt) 2019-03-01
SI2378876T1 (sl) 2019-05-31
US20110021555A1 (en) 2011-01-27
IL255163B (en) 2019-01-31
IL213628A (en) 2017-11-30
EP2378876A1 (en) 2011-10-26
AU2009335943A1 (en) 2013-10-24
US20200276182A1 (en) 2020-09-03
US20110257218A1 (en) 2011-10-20
US8236816B2 (en) 2012-08-07
US20110257216A1 (en) 2011-10-20
US8222270B2 (en) 2012-07-17
RS58566B1 (sr) 2019-05-31
PA8855101A1 (es) 2010-07-27
EP2378876A4 (en) 2012-12-05
US20110257217A1 (en) 2011-10-20
CO6400171A2 (es) 2012-03-15
ES2720149T3 (es) 2019-07-18
DOP2011000195A (es) 2011-12-15
MX2011001555A (es) 2011-04-14
MX346455B (es) 2017-03-21
US10238644B2 (en) 2019-03-26
US8299109B2 (en) 2012-10-30

Similar Documents

Publication Publication Date Title
HUE041944T2 (hu) Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére
HUS2100018I1 (hu) Hatóanyagok légúti beadására alkalmas készítmények és ezekkel kapcsolatos eljárások
IL255752B (en) Compounds, pharmaceutical compositions comprising the same and uses thereof for treating cardiovasclar disease, an inflammatory disease or cancer
HUE037082T2 (hu) Új lipidek és készítmények terápiás hatóanyagok szállítására
EA201201509A1 (ru) Фармацевтические составы, содержащие пиоглитазон и линаглиптин
WO2011088120A8 (en) Antibody formulation and therapeutic regimens
HUE036780T2 (hu) Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
BR112014010186A2 (pt) formulação farmacêutica estável, kit, composição farmacêutica, método para preparar uma formulação farmacêutica, e, método para tratar um humano ou animal
BR112013009708A2 (pt) aparelhos, métodos e composições para tratamento endodôntico
BRPI1016147A2 (pt) sistema intrauterino para uso no tratamento de uma condição médica, e, método para a fabricação de um sistema intrauterino
BR112014010299A2 (pt) composição para prevenir e tratar doenças da cavidade oral; método de prevenção e tratamento de doenças da cavidade oral; e uso da composição
BR112012022879A2 (pt) composto, composição farmacêutica, uso do composto e método de tratamento
EP2542255A4 (en) METHOD AND COMPOSITIONS FOR TREATING THE DEGOS SYNDROME
CY2016053I2 (el) Μεθοδοι αγωγης χρησιμοποιωντας φαρμακευτικες ουσιες συλληψης αμμωνιας
HK1199401A1 (en) Pharmaceutical formulations and the use thereof for the treatment of peanut allergy
GB2479213B (en) Pharmaceutical formulations for the treatment of overactive bladder
CL2014000849A1 (es) Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas.
IT1402018B1 (it) Formulazioni per il trattamento delle affezioni delle prime vie respiratorie.
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
ZA201203281B (en) Pharmaceutical combinations, pharmaceutical compositions, medicament and method for the treatment of animals
BR112013015798A2 (pt) composição de agente de formação de imagem, método de preparar uma composição de agente de formação de imagem, e, composição farmacêutica
BR112013010709A2 (pt) derivado de ácido trans-2-decenoico e agente farmacêutico contendo o mesmo
HUE054171T2 (hu) Paracetamolt tartalmazó gyógyászati kompozíciók és ejárás azok elõállítására
BR112013009647A2 (pt) derivado de vitamina, composição farmacêutica, agente terapêutico, e, composto